Hypertensive disorders during pregnancy, encompassing chronic hypertension with or without superimposed pre-eclampsia/eclampsia, gestational hypertension, preeclampsia with or without severe features, HELLP syndrome, and eclampsia, pose significant threats to both maternal and fetal well-being. Effective prenatal care, characterized by meticulous monitoring for signs of end-organ damage and timely intervention to mitigate adverse effects, has led to a reduction in morbidity and mortality. However, these risks remain a major concern. While hypertension itself presents challenges in pregnancy, the progression to pre-eclampsia/eclampsia and HELLP syndrome are particularly worrisome. This article provides a comprehensive review of the evaluation and management of hypertensive disorders in pregnancy, emphasizing the crucial role of differential diagnosis in prenatal care and the importance of an interprofessional team approach to optimize patient outcomes.
Understanding Hypertension in Pregnancy: Etiology and Risk Factors
Several conditions can compromise uteroplacental blood flow and vascular function, thereby increasing the risk of hypertensive disorders during pregnancy. These include pre-existing hypertension, renal disease, diabetes mellitus, obstructive sleep apnea (OSA), thrombophilia, and autoimmune diseases. Furthermore, women with specific histories and characteristics are at a heightened risk of developing gestational hypertension and progressing to pre-eclampsia. These risk factors include:
- Previous history of preeclampsia
- Prior HELLP syndrome
- Twin or multiple pregnancies
- Body Mass Index (BMI) >30
- Autoimmune disease
- Age over 35 years
- Nulliparity (first-time mothers)
- Family history of gestational hypertension (mother or sister)
Identifying these risk factors during prenatal care is the first step in differential diagnosis and allows for closer monitoring and early intervention strategies.
Epidemiology of Hypertensive Disorders in Pregnancy
Hypertensive disorders are a common complication of pregnancy, affecting between 5% and 10% of all pregnancies. Preeclampsia, a significant concern, complicates 2-8% of pregnancies globally. In the United States, the incidence of preeclampsia saw a concerning 25% increase between 1987 and 2004. The overall rise in hypertension during pregnancy is attributed to shifts in maternal demographics, such as advancing maternal age and increased pre-pregnancy weight.
Conversely, the incidence of eclampsia has declined due to advancements in prenatal care. These improvements include enhanced antenatal therapies like blood pressure management, magnesium seizure prophylaxis, and timely delivery via induction of labor or Cesarean section, which effectively resolves preeclampsia/eclampsia. This underscores the positive impact of prenatal care and proactive management in mitigating the most severe complications of hypertensive disorders.
Pathophysiology: Unraveling the Mechanisms of Hypertension in Pregnancy
The precise pathophysiology of hypertension in pregnancy remains incompletely understood, but current research highlights the critical role of abnormal trophoblast differentiation during endothelial invasion. This process, disrupted by dysregulation or altered production of cytokines, adhesion molecules, major histocompatibility complex molecules, and metalloproteinases, is central to the development of gestational hypertensive diseases. These molecular imbalances lead to impaired development and remodeling of spiral arteries in the deep myometrial tissues, resulting in placental hypoperfusion and ischemia.
Emerging research emphasizes the role of antiangiogenic factors released by the placenta. These factors contribute to systemic endothelial dysfunction, a key mechanism in systemic hypertension. Organ hypoperfusion due to endothelial dysfunction frequently affects the eyes, lungs, liver, kidneys, and peripheral vasculature. It’s widely accepted that the underlying causes are multifactorial, making differential diagnosis in prenatal care crucial for tailored management.
History, Physical Examination, and Symptom Presentation
In both chronic and gestational hypertension, physical examination findings are often limited to elevated blood pressure readings: systolic blood pressure above 140 mmHg and/or diastolic blood pressure above 90 mmHg. Severe hypertension is defined as systolic blood pressure exceeding 160 mmHg and/or diastolic blood pressure above 110 mmHg.
Edema, particularly an increase in baseline edema, is commonly observed in preeclampsia. Severe features of preeclampsia can manifest with a range of symptoms indicating end-organ involvement:
- Cerebral Symptoms: Unremitting or severe headache, altered mental status
- Visual Symptoms: Scotomata (blind spots), photophobia (light sensitivity), blurred vision, temporary blindness or visual field defects
- Pulmonary Edema: Dyspnea (shortness of breath), rales (crackling sounds in lungs) on auscultation
- Renal Impairment: Water retention leading to peripheral edema
- Hepatic Impairment: Right upper quadrant pain
HELLP syndrome, a severe variant of preeclampsia, often presents with malaise and right upper quadrant pain in up to 90% of cases, accompanied by vomiting. Recognizing these varied presentations is vital for accurate differential diagnosis during prenatal assessments.
Evaluation and Diagnostic Criteria in Prenatal Care
Accurate diagnosis is fundamental in managing hypertensive disorders of pregnancy. Differential diagnosis in prenatal care relies on established guidelines and careful evaluation.
Chronic Hypertension: According to ACC/AHA and ACOG guidelines, chronic hypertension is diagnosed based on in-office blood pressure measurements exceeding 140/90 mmHg, confirmed by ambulatory blood pressure monitoring, home blood pressure monitoring, or serial office visits with elevated pressures at least 4 hours apart, and documented before 20 weeks of gestation.
Gestational Hypertension: Gestational hypertension is defined by ACOG guidelines as blood pressure readings of 140/90 mmHg or higher on two separate occasions at least 4 hours apart, occurring after 20 weeks of gestation in a woman with previously normal blood pressure. In cases of severe hypertension (systolic >160mmHg or diastolic >110mmHg), gestational hypertension can be confirmed with a similar reading after a shorter interval to facilitate prompt antihypertensive treatment. Clinical symptoms typically manifest when blood pressure exceeds 160/110 mmHg and may indicate end-organ damage.
Preeclampsia: Preeclampsia diagnosis, as per ACOG guidelines, requires meeting the hypertension criteria along with proteinuria, defined as ≥300mg of protein excretion in a 24-hour urine collection or a protein/creatinine ratio ≥0.3. A urine dipstick showing a protein reading of ≥1+ can be used if other methods are unavailable.
Importantly, preeclampsia can be diagnosed in the absence of proteinuria if new-onset hypertension is accompanied by any of the following:
- Thrombocytopenia (platelet count <100,000 x10(9)/L)
- Renal insufficiency (doubling of baseline serum creatinine or serum creatinine >1.1mg/dL)
- Pulmonary edema
- Impaired liver function (AST/ALT greater than twice the upper limit of normal)
- New-onset headache unresponsive to medication without alternative cause
Preeclampsia can be superimposed on chronic hypertension or represent progression from gestational hypertension. Severe features of preeclampsia are defined by systolic blood pressure >160mmHg or diastolic blood pressure >110mmHg on two occasions 4 hours apart, or any severe range pressure requiring urgent antihypertensive treatment (within minutes, 10-30 minutes apart).
Eclampsia: Eclampsia is diagnosed when a preeclamptic patient develops generalized tonic-clonic seizures, typically intrapartum or within 72 hours postpartum, due to untreated or undertreated preeclampsia. Eclampsia occurs in approximately 2-3% of women with severe preeclampsia features who do not receive seizure prophylaxis and up to 0.6% of women with preeclampsia without severe features. Maternal complications are substantial, occurring in up to 70% of eclampsia cases, with maternal morbidity as high as 14%.
HELLP Syndrome: HELLP syndrome, a severe form of preeclampsia, is defined by its namesake criteria: Hemolysis, Elevated Liver enzymes, and Low Platelet count. ACOG criteria include:
- Hemolysis: LDH >600IU/L
- Elevated Liver Enzymes: AST and/or ALT >2 times the upper limit of normal
- Thrombocytopenia: Platelet count <100,000 x 10(9)/L
These diagnostic criteria are essential for accurate differential diagnosis in prenatal care, guiding appropriate management strategies for each hypertensive disorder.
Treatment and Management Strategies
Management strategies for hypertensive disorders in pregnancy are tailored to the specific diagnosis and severity.
Prophylaxis: Low-dose aspirin (81mg) is recommended for preeclampsia prevention, initiated between 12-28 weeks and continued until delivery for women with one high-risk factor or two or more moderate risk factors. High-risk factors include a history of preeclampsia, chronic hypertension, diabetes (type 1 or 2), renal disease, autoimmune disease (especially SLE or antiphospholipid syndrome), or multifetal gestation. Moderate risk factors include nulliparity, pregnancy interval >10 years, BMI >30, low socioeconomic status, African American race, family history of preeclampsia in a first-degree relative, advanced maternal age (≥35 years), IUGR, or previous adverse pregnancy outcome.
Antihypertensive Treatment: Treatment for gestational and chronic hypertension is indicated when blood pressures are in the severe range (>160/110 mmHg) and sustained for at least 15 minutes. ACOG guidelines recommend antihypertensive treatment for chronic hypertension at levels of 140/90 mmHg. First-line antihypertensive agents include labetalol, hydralazine, or nifedipine. Nifedipine is preferred for acute oral treatment, while nifedipine or oral labetalol are preferred in outpatient settings. Thiazide diuretics can be continued if used pre-pregnancy for chronic hypertension. ACE inhibitors, angiotensin receptor blockers, mineralocorticoid receptor antagonists, and nitroprusside are teratogenic and contraindicated in pregnancy, except for nitroprusside as a last resort in treatment-resistant hypertension. The target blood pressure range is 140-150/90-100 mmHg.
Preeclampsia with Severe Features Management: Magnesium seizure prophylaxis is indicated for preeclampsia with severe features and continued until after delivery and adequate diuresis. Antenatal corticosteroids are recommended to promote fetal lung maturity if gestational age is between 24 0/7 weeks and 33 6/7 weeks and delivery is anticipated due to preeclampsia, eclampsia, or other concerns (some providers may administer steroids up to 35 6/7 weeks EGA).
Monitoring and Delivery: Increased maternal and fetal monitoring is crucial for chronic hypertension, gestational hypertension, and preeclampsia due to risks of intrauterine growth restriction, placental abruption, and impaired placental/umbilical blood flow. Monitoring may include twice-weekly blood pressure assessments, fetal non-stress tests, amniotic fluid index evaluation, and laboratory tests. Abnormal findings may necessitate early delivery.
Definitive treatment for gestational hypertension, preeclampsia, and eclampsia is delivery. Maternal symptoms typically resolve rapidly postpartum. Delivery timing is determined by balancing fetal maturity against hypertensive/preeclamptic risks. ACOG guidelines recommend delivery as early as 34+0/7 weeks EGA for preeclampsia with severe features or immediately for unstable maternal or fetal conditions. For gestational hypertension or preeclampsia without severe features, delivery can be safely delayed until 37+0/7 weeks EGA or at diagnosis if after 37+0/7 weeks with reassuring antepartum testing. Induction for chronic hypertension is recommended between 38 0/7 and 39 6/7 weeks gestation.
Differential Diagnosis of Hypertension in Pregnancy
A comprehensive differential diagnosis is crucial in prenatal care to accurately identify and manage hypertensive disorders. The differential diagnoses for hypertension in pregnancy include:
- Antiphospholipid Syndrome: An autoimmune disorder associated with recurrent pregnancy loss, thrombosis, and hypertension.
- Aortic Coarctation: A congenital narrowing of the aorta that can cause secondary hypertension.
- Cushing Syndrome: A rare endocrine disorder resulting from prolonged exposure to elevated levels of cortisol, which can cause hypertension.
- Eclampsia: Seizure activity in the setting of preeclampsia, representing a severe progression.
- Glomerulonephritis: Kidney inflammation that can lead to hypertension and proteinuria.
- Hydatiform Mole: A gestational trophoblastic disease that, although rare, can present with early-onset preeclampsia-like symptoms.
- Conn Syndrome (Primary Aldosteronism): An endocrine disorder characterized by excessive aldosterone production, leading to hypertension.
- Hyperthyroidism: An overactive thyroid gland can sometimes contribute to hypertension.
- Malignant Hypertension: A severe and rapidly progressive form of hypertension with evidence of end-organ damage.
Differentiating between these conditions and the various hypertensive disorders of pregnancy is essential for appropriate and targeted management during prenatal care. Thorough history taking, physical examination, and specific laboratory investigations are necessary to refine the differential diagnosis and guide treatment decisions.
Potential Complications of Hypertensive Disorders
Hypertensive disorders in pregnancy can lead to a range of serious complications for both mother and fetus:
- Eclamptic seizures
- Intracranial hemorrhage
- Pulmonary edema
- Renal failure
- Coagulopathy (disorders of blood clotting)
- Hemolysis (destruction of red blood cells)
- Liver injury
- Thrombocytopenia (low platelet count)
- Intra-uterine growth restriction (IUGR)
- Oligohydramnios (low amniotic fluid)
- Placental abruption (premature separation of the placenta)
- Nonreassuring fetal status
These complications underscore the importance of early detection, accurate differential diagnosis, and effective management of hypertensive disorders through comprehensive prenatal care.
Enhancing Healthcare Team Outcomes
Optimal management of hypertension in pregnancy requires a collaborative, interprofessional team, including a cardiologist, obstetrician, dietitian, physical therapist, and nurse. Primary prevention is key. While there is no guaranteed way to prevent hypertension during pregnancy, lifestyle modifications are crucial. Patients should be encouraged to adopt healthy habits:
- Increase physical activity
- Maintain a healthy diet
- Avoid excessive weight gain
Regular prenatal follow-up is essential, and patients should be educated on home blood pressure monitoring. Smoking and alcohol should be avoided, and intake of sugary foods minimized. This holistic, team-based approach optimizes outcomes for pregnant women with hypertensive disorders.
Outcomes and Long-Term Implications
Hypertension during pregnancy is associated with significant maternal and fetal morbidity and mortality. In the US, it contributes to 2-7% of maternal deaths annually. Transient hypertension during pregnancy can increase the risk of developing chronic hypertension later in life. Furthermore, hypertensive disorders of pregnancy are linked to fetal growth restriction and placental abruption. Long-term cardiovascular health of women with a history of hypertensive pregnancy disorders needs to be considered, highlighting the importance of postpartum follow-up and risk factor management.
Review Questions
(Note: Review questions are not included as per the user’s request to exclude extra elements)
References
1.Fisher SC, Van Zutphen AR, Werler MM, Romitti PA, Cunniff C, Browne ML., National Birth Defects Prevention Study. Maternal antihypertensive medication use and selected birth defects in the National Birth Defects Prevention Study. Birth Defects Res. 2018 Nov 15;110(19):1433-1442. [PMC free article: PMC10064868] [PubMed: 30260586]
2.Spiro L, Scemons D. Management of Chronic and Gestational Hypertension of Pregnancy: A Guide for Primary Care Nurse Practitioners. Open Nurs J. 2018;12:180-183. [PMC free article: PMC6128013] [PubMed: 30258507]
3.Holm L, Stucke-Brander T, Wagner S, Sandager P, Schlütter J, Lindahl C, Uldbjerg N. Automated blood pressure self-measurement station compared to office blood pressure measurement for first trimester screening of pre-eclampsia. Health Informatics J. 2019 Dec;25(4):1815-1824. [PubMed: 30253712]
4.Miller MJ, Butler P, Gilchriest J, Taylor A, Lutgendorf MA. Implementation of a standardized nurse initiated protocol to manage severe hypertension in pregnancy. J Matern Fetal Neonatal Med. 2020 Mar;33(6):1008-1014. [PubMed: 30231657]
5.Dymara-Konopka W, Laskowska M, Oleszczuk J. Preeclampsia – Current Management and Future Approach. Curr Pharm Biotechnol. 2018;19(10):786-796. [PubMed: 30255751]
6.Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin Summary, Number 222. Obstet Gynecol. 2020 Jun;135(6):1492-1495. [PubMed: 32443077]
7.Timpka S, Markovitz A, Schyman T, Mogren I, Fraser A, Franks PW, Rich-Edwards JW. Midlife development of type 2 diabetes and hypertension in women by history of hypertensive disorders of pregnancy. Cardiovasc Diabetol. 2018 Sep 10;17(1):124. [PMC free article: PMC6130069] [PubMed: 30200989]
8.Catov JM, Countouris M, Hauspurg A. Hypertensive Disorders of Pregnancy and CVD Prediction: Accounting for Risk Accrual During the Reproductive Years. J Am Coll Cardiol. 2018 Sep 11;72(11):1264-1266. [PubMed: 30190004]
9.Yang YY, Fang YH, Wang X, Zhang Y, Liu XJ, Yin ZZ. A retrospective cohort study of risk factors and pregnancy outcomes in 14,014 Chinese pregnant women. Medicine (Baltimore). 2018 Aug;97(33):e11748. [PMC free article: PMC6113036] [PubMed: 30113460]
10.Colussi G, Catena C, Driul L, Pezzutto F, Fagotto V, Darsiè D, Badillo-Pazmay GV, Romano G, Cogo PE, Sechi LA. Secondary hyperparathyroidism is associated with postpartum blood pressure in preeclamptic women and normal pregnancies. J Hypertens. 2021 Mar 01;39(3):563-572. [PubMed: 33031174]
11.American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 203: Chronic Hypertension in Pregnancy. Obstet Gynecol. 2019 Jan;133(1):e26-e50. [PubMed: 30575676]
12.Ishikawa T, Obara T, Nishigori H, Miyakoda K, Ishikuro M, Metoki H, Ohkubo T, Sugawara J, Yaegashi N, Akazawa M, Kuriyama S, Mano N. Antihypertensives prescribed for pregnant women in Japan: Prevalence and timing determined from a database of health insurance claims. Pharmacoepidemiol Drug Saf. 2018 Dec;27(12):1325-1334. [PubMed: 30252182]
13.Gonzalez Suarez ML, Kattah A, Grande JP, Garovic V. Renal Disorders in Pregnancy: Core Curriculum 2019. Am J Kidney Dis. 2019 Jan;73(1):119-130. [PMC free article: PMC6309641] [PubMed: 30122546]
14.Katigbak C, Fontenot HB. A Primer on the New Guideline for the Prevention, Detection, Evaluation, and Management of Hypertension. Nurs Womens Health. 2018 Aug;22(4):346-354. [PubMed: 30077241]
15.ACOG Practice Bulletin No. 202: Gestational Hypertension and Preeclampsia. Obstet Gynecol. 2019 Jan;133(1):1. [PubMed: 30575675]
16.ACOG Committee Opinion No. 743: Low-Dose Aspirin Use During Pregnancy. Obstet Gynecol. 2018 Jul;132(1):e44-e52. [PubMed: 29939940]
17.Smith GN, Pudwell J, Saade GR. Impact of the New American Hypertension Guidelines on the Prevalence of Postpartum Hypertension. Am J Perinatol. 2019 Mar;36(4):440-442. [PubMed: 30170330]
18.Hauspurg A, Sutton EF, Catov JM, Caritis SN. Aspirin Effect on Adverse Pregnancy Outcomes Associated With Stage 1 Hypertension in a High-Risk Cohort. Hypertension. 2018 Jul;72(1):202-207. [PMC free article: PMC6002947] [PubMed: 29802215]
19.Hitti J, Sienas L, Walker S, Benedetti TJ, Easterling T. Contribution of hypertension to severe maternal morbidity. Am J Obstet Gynecol. 2018 Oct;219(4):405.e1-405.e7. [PubMed: 30012335]
20.Du MC, Ouyang YQ, Nie XF, Huang Y, Redding SR. Effects of physical exercise during pregnancy on maternal and infant outcomes in overweight and obese pregnant women: A meta-analysis. Birth. 2019 Jun;46(2):211-221. [PubMed: 30240042]
Disclosures: Richard Luger declares no relevant financial relationships with ineligible companies.
Disclosures: Benjamin Kight declares no relevant financial relationships with ineligible companies.
